>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance:

ALIM +20%, SQ +19.3%, ETRM +17.9%, XPO +12.3%, AXGN +11.4%, AVEO +9.6%, PODD +8.6%, EXEL +8.5%, NSTG+8.3%, JACK +7.8%, GDDY +7.7%, (also names new CFO), AKRX +7.6%, GOGO +7.1%
AVID +6.4%, ERII +6.1%, EPE +6.1%, KTWO +6%, SNCR +5.9%, MX +5.9%, FXCM +5.5%, AV +5%, CSII +4.9%,CTB +4.6%, FIVN +4.5%, IO +4.4%, HSC +4.3%, SYN +4.2%, NSIT +4%
COT +3.9%, DNR +3.8%, MASI +3.6%, NLST +3.3%, SXL +2.8%, HL +2.8%, NGL +2.8%, ICPT +2.6%, TROX +2.5%,EVA +2.5%, PE +2.4%, HLF +2.4%, EVC +2.4%, BTG +2.2%, CNAT +2.1%, AREX +2%, HRTG +2%,
CHD +1.4%, ZUMZ +1.3%, (Zumiez Inc reports July same store sales -2.9% vs -7.6% Retail Metrics consensus; Q2 (Jul), sees Q2 EPS at high end or slightly better than prior guidance ($0.09)-(0.13) vs. ($0.09) Capital IQ Consensus Estimate primarily due to higher than planned sales), RIG +1.3%, LPI +1.3%, BLL +1.3%, MFC +1.3%, AGO +1.2%, FLXN +1%,HGG +0.9%, HRC +0.9%

Other news:

OCUL +23.6% (updates on its NDA for DEXTENZA; FDA issued a letter noting that corrective actions detailed in its responses as a whole appear to address the ten inspectional observations raised)
ICLD +21.3% (receives over $6.0 million in new contracts and purchase orders for professional services, network services and maintenance for new and existing customers)
CHEK +18.7% (enters into an agreement with GE Healthcare (GE) to develop and validate high-volume manufacturing for X-ray source production and assembly into its capsule)
ANTH +6.4% (announces completion of dosing in CHABLIS-SC1 Phase 3 clinical study with Blisibimod )
OMER +4.1% (announces results from its OMS906 complement program; OMS906 significantly reduced both incidence and severity of disease in a well-established animal model of arthritis mediated by the APC)
MASI +3.6% (announces the CE marking for the pediatric indication for O3 regional oximetry with the O3 pediatric sensor)
TOPS +3.1% ( enters into a senior secured facility with a major northern European bank for the financing of the M/T Nord Valiant)
ZIOP +2.9% (announces the publication of data highlighting the benefits of using the non-viral Sleeping Beauty system to genetically modify T-cells to express a CAR for use against leukemias and lymphomas)

Analyst comments: